Epigenetic and immune- signaling clues in candida bloodstream infections
Official title: Epigenomic Mechanisms & STAT Networks in Persistent CA Candidemia
Funded at Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · NIH-11350999 · Data updated 2026-11-12
This grant looks at why Candida infections in the blood can be deadly and how patient genes and immune responses might explain who struggles or survives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center NIH-funded |
| Lab location | 1 site (Torrance, United States) |
| Project start | August 10, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $285,264 |
| NIH project number | 5U19AI172713-04 |
| Project ID | NIH-11350999 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with candidemia who have or had persistent infection, from the study cohort or similar cases at participating centers.
✕Less likely to help
Patients without candidemia or without access to similar biorepositories may not directly benefit.
What this research studies
In hospitalized adults with blood infections from Candida albicans, this project will study stored patient and fungal samples to connect genetic and epigenetic features with outcomes. Researchers will compare those who died to matched survivors and examine serial fungal isolates from persistent cases. The goal is to map how the fungus and the patient’s biology interact to drive persistent infection and death, with a focus on epigenetics, immune signals, and relevant pathways. Findings could point to new ways to diagnose, prevent, or treat hematogenously spread candidiasis.
Why it matters
Potential benefit: A deeper understanding of why some patients with candidemia fare worse may lead to better diagnostic markers and targeted treatments in the future.
How similar studies have gone: Previous work shows that host and pathogen factors influence outcomes in candidemia, but this project aims to integrate genomic and epigenetic data for deeper insights.
Where this research is happening
-
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, United States Active
Researchers
- Principal investigator: Filler, Scott G — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Study coordinator: Filler, Scott G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.